Obesity treatments are evolving, and one pharmaceutical giant is making headlines with a tiny but mighty pill. Eli Lilly, a company with over 140 years of history in innovation, is stepping into uncharted territory with its oral GLP-1 weight-loss drug, orforglipron—a potential game-changer in a market dominated by injectables.

Join Dan Koh and Emaad Akhtar as they tear down the story behind the company, the science behind orforglipron, and what it means for investors and the future of healthcare.